MELAG

MELAG. We introduce ourselves.

Quality and innovation - the factors behind the success of a family company

We are an owner-managed family company and have been focusing consistently on products for practice hygiene since we were founded in 1951. This concentration means that for us as a medium-sized company it is possible to further develop our brands with a team of highly qualified, specialist engineers at a top international level.

Today, we are by far the largest manufacturer of practice sterilizers and thermal disinfectors to manufacture exclusively these products. We are convinced that the consistent specialisation is an important condition for the high quality of our product range. You, our customers, justifiably demand optimal products, quality and reliability from us. Through the consistent realisation of our guiding principles “competence in hygiene” and “quality - made in Germany”, we guarantee that we will meet these requirements.

It is our aim to make an important contribution so you are successful in your daily work in the field of instrument decontamination and hygiene.

The management and the entire MELAG team

Innovations

With devices for the entire practice workflow from steam sterilizers, thermal disinfectors and water treatment units to products for the storage of sterile goods and documentation of this, we want to make our customers’ work safer and more efficient. Through our daily work we protect patients and practice teams to an even greater extent against infections. We do not make any compromises and we guarantee the best quality “made in Germany”.

With the more than 145 excellently trained engineers we have today who work exclusively in the area of our core skills, we have managed to win over our discerning customers around the world with our high quality standards, high levels of safety, reliability and system properties of our products, which can be integrated as well as possible.

As a global leader with more than 65 years of experience in the field of hygiene, we invest almost 25% of our revenue into research and development to further develop our products and develop new, ever more innovative products that contribute to a decrease in the risk of infection as a result of treatments and therefore make a significant contribution to global health.

2015